Systemic immune changes accompany combination treatment with immunotoxin <scp>LMB</scp> ‐100 and nab‐paclitaxel-Reference-Cited by-同舟云学术

Systemic immune changes accompany combination treatment with immunotoxin LMB ‐100 and nab‐paclitaxel

Published:2022-10-08 Issue:4 Volume:12 Page:4236-4249
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Pegna Guillaume Joe¹²³,Lee Min‐Jung⁴,Peer Cody J.⁵,Ahmad Mehwish I.⁶⁷,Venzon David J.⁸,Yu Yunkai⁹,Yuno Akira⁴¹⁰,Steinberg Seth M.⁸,Cao Liang⁹,Figg William D.⁵,Donahue Renee N.¹¹,Hassan Raffit¹²,Pastan Ira¹,Trepel Jane B.⁴,Alewine Christine¹^ORCID

Affiliation:

1. Laboratory of Molecular Biology National Cancer Institute, National Institutes of Health Bethesda Maryland USA

2. Medical Oncology Program National Cancer Institute, National Institutes of Health Bethesda Maryland USA

3. Knight Cancer Institute Oregon Health & Science University Portland Oregon USA

4. Developmental Therapeutics Branch National Cancer Institute, National Institutes of Health Bethesda Maryland USA

5. Clinical Pharmacology Program National Cancer Institute, National Institutes of Health Bethesda Maryland USA

6. Office of Research Nursing National Cancer Institute, National Institutes of Health Bethesda Maryland USA

7. Astra Zeneca Gaithersburg Maryland USA

8. Biostatistics and Data Management Section National Cancer Institute, National Institutes of Health Bethesda Maryland USA

9. Genetics Branch National Cancer Institute, National Institutes of Health Bethesda Maryland USA

10. Oral and Maxillofacial Surgery Kumamoto University Hospital Kumamoto Japan

11. Laboratory of Tumor Immunology and Biology National Cancer Institute, National Institutes of Health Bethesda Maryland USA

12. Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research National Cancer Institute, National Institutes of Health Bethesda Maryland USA

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.5290

Reference45 articles.

1. Cancer statistics, 2018

2. An Algorithmic Approach to the Diagnosis of Pancreatic Neoplasms

3. Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

4. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

5. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers;Frontiers in Oncology;2024-04-19

2. Innate and adaptive immune-directed tumour microenvironment in pancreatic ductal adenocarcinoma;Frontiers in Immunology;2024-02-07